Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
Syngene's collaboration with Zoetis started in 2011
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Dupixent peak sales ambition raised to more than €13 billion
Subscribe To Our Newsletter & Stay Updated
